Overall, GLP-1 RA reduced CV mortality by 13% (HR 0.87, 95% CI 0.80 to 0.94) and ACM by 12% (HR 0.88, 95% CI 0.82 to 0.94), with no increase in the risk of severe hypoglycemia, retinopathy, or pancreatic adverse effects. The gene discussed is GCG; the disease is retinal disorder.